DMD Simcyp

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Pichette, V.
Right arrow Articles by du Souich, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pichette, V.
Right arrow Articles by du Souich, P.

Vol. 27, Issue 1, 81-85, January 1999

Role of Plasma Protein Binding on Renal Metabolism and Dynamics of Furosemide in the Rabbit

Vincent Pichette, David Geadah, and Patrick du Souich

Service de néphrologie, Hopital Maisonneuve-Rosemont and Département de Pharmacologie, Faculté de Médecine, Université de Montréal

To investigate the influence of furosemide plasma protein binding on its kinetics and dynamics, the kinetics of furosemide was studied in the presence of a protein binding displacer, warfarin, and in hypoalbuminemic rabbits. Compared with controls, in anesthetized rabbits pretreated with warfarin, the unbound fraction of furosemide increased from 1.8 ± 0.4% to 7.0 ± 0.4% (p < .001), and its metabolic clearance increased by 30%, whereas furosemide urinary excretion decreased by 48% (p < .05). Experiments in nephrectomized rabbits showed that the increase in metabolic clearance was secondary to an increase in its renal metabolic clearance (p < .05). Compared with controls, in warfarin pretreated rabbits, sodium excretion and diuresis were decreased by 30% (p < .05). However, when furosemide was injected mixed with albumin, warfarin-induced kinetic and dynamic alterations of furosemide were reversed. Compared with control rabbits, in conscious hypoalbuminemic rabbits, furosemide unbound fraction was enhanced from 1.2 ± 0.1% to 5.5 ± 0.5% (p < .001), and its urinary excretion, diuresis, and sodium excretion were reduced by 22% (p < .05). The administration of warfarin to hypoalbuminemic rabbits further increased the fraction of unbound furosemide, and diminished its urinary excretion and diuretic effect. In conclusion, 1) binding of furosemide to plasma proteins, and not albumin per se, facilitates its renal secretion and pharmacological response; 2) the decrease in furosemide binding, secondary to drug displacement and/or hypoalbuminemia, can be a cause of resistance to the diuretic; and 3) when furosemide binding is decreased, the administration of furosemide mixed with albumin enhances its renal secretion and diuretic effect.


Copyright © 1999 by The American Society for Pharmacology and Experimental Therapeutics



This article has been cited by other articles:


Home page
Br J AnaesthHome page
F. Cavaliere, G. Conti, U. Moscato, F. Meo, M. A. Pennisi, R. Costa, and R. Proietti
Hypoalbuminaemia does not impair Diprifusor performance during sedation with propofol
Br. J. Anaesth., April 1, 2005; 94(4): 453 - 458.
[Abstract] [Full Text] [PDF]


Home page
J. Am. Soc. Nephrol.Home page
C. S. Wilcox
New Insights into Diuretic Use in Patients with Chronic Renal Disease
J. Am. Soc. Nephrol., March 1, 2002; 13(3): 798 - 805.
[Abstract] [Full Text] [PDF]


Home page
Drug Metab. Dispos.Home page
G. Castaneda-Hernandez, J. Verges, V. Pichette, L. Heroux, G. Caille, and P. du Souich
Input Rate as a Major Determinant of Furosemide Pharmacodynamics: Influence of Fluid Replacement and Hypoalbuminemia
Drug Metab. Dispos., March 1, 2000; 28(3): 323 - 328.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 1999 by the American Society for Pharmacology and Experimental Therapeutics.